María Elena Cabrera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
María Elena Cabrera has a total of 320 co-authors. Here are the top co-authors by number of shared publications:
- Camila Peña
Hospital del Salvador, Santiago, Chile
8 shared publications Massimo Federico
Chimomo Department, University of Modena and Reggio Emilia
6 shared publications- Jorge J. Castillo
Bing Center for Waldenstrom's Macroglobulinemia Dana‐Farber Cancer Institute Boston MA USA
5 shared publications - Francine M. Foss
Yale University School of Medicine
4 shared publications Alvaro Pizarro
Hospital San Borja Arriaran, Santiago, Chile
3 shared publicationsBernardita Rojas
Hospital Carlos van Buren, Valparaíso, Chile
3 shared publications
Latest Publications
- 14 March 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (6) , 1440-1446
Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium
Approximately 10% of all cancers worldwide have been attributed to an underlying viral infection [1]. Regarding lymphoid malignancies, viral infections have been linked to several of these cancers ...
- 14 March 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (6) , 1440-1446
Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium
Approximately 10% of all cancers worldwide have been attributed to an underlying viral infection [1]. Regarding lymphoid malignancies, viral infections have been linked to several of these cancers ...
- Open Access
- 12 February 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (7) , 755-767
Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium
We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 (36.5%) had TTR12, 181 (40%) relapsed at ≥12 months, and 106 (23.5%) remained relapse-free. TTR12 conferred worse OS using m-LM (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.58-2.90; P< .001), s-LM (HR, 1.92; 95% CI, 1.39-2.66; P< .001); and td-Cox (HR, 5.81; 95% CI, 2.94-11.46; P< .001). Results were consistent in the independent validation cohorts. TTR12 consistently conferred worse OS irrespective of frontline stem cell transplantation or PIT score, in peripheral T-cell lymphoma, not otherwise specified (m-LM: HR, 2.32; 95% CI, 1.51-3.55; P< .001; s-LM: HR, 2.10; 95% CI, 1.33-3.31; P = .001), anaplastic large cell lymphoma (m-LM: HR, 3.34; 95% CI, 1.18-9.50; P = .023; s-LM: HR, 2.96; 95% CI, 1.02-8.81; P = .046), and angioimmunoblastic T-cell/T follicular helper cell lymphoma (m-LM only: HR, 1.92; 95% CI, 1.15-3.21; P = .013). Second-line novel therapies improved OS (second-line start to death) vs chemotherapy in TTR12 only (HR, 0.60; 95% CI, 0.37-0.97; P = .038; without TTR12: HR, 0.82; 95% CI, 0.51-1.32; P = .407). TTR12 serves as a prognostic and potential OS surrogate marker, supporting stratification of new risk groups and need for their differential treatment.
- 12 February 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (7) , 755-767
Open AccessEarly time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium
We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 (36.5%) had TTR12, 181 (40%) relapsed at ≥12 months, and 106 (23.5%) remained relapse-free. TTR12 conferred worse OS using m-LM (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.58-2.90; P< .001), s-LM (HR, 1.92; 95% CI, 1.39-2.66; P< .001); and td-Cox (HR, 5.81; 95% CI, 2.94-11.46; P< .001). Results were consistent in the independent validation cohorts. TTR12 consistently conferred worse OS irrespective of frontline stem cell transplantation or PIT score, in peripheral T-cell lymphoma, not otherwise specified (m-LM: HR, 2.32; 95% CI, 1.51-3.55; P< .001; s-LM: HR, 2.10; 95% CI, 1.33-3.31; P = .001), anaplastic large cell lymphoma (m-LM: HR, 3.34; 95% CI, 1.18-9.50; P = .023; s-LM: HR, 2.96; 95% CI, 1.02-8.81; P = .046), and angioimmunoblastic T-cell/T follicular helper cell lymphoma (m-LM only: HR, 1.92; 95% CI, 1.15-3.21; P = .013). Second-line novel therapies improved OS (second-line start to death) vs chemotherapy in TTR12 only (HR, 0.60; 95% CI, 0.37-0.97; P = .038; without TTR12: HR, 0.82; 95% CI, 0.51-1.32; P = .407). TTR12 serves as a prognostic and potential OS surrogate marker, supporting stratification of new risk groups and need for their differential treatment.
- Open Access
- 17 September 2025
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 47 (4) , 103982
Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in the public Chilean national health system: A single center study
- 17 September 2025
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 47 (4) , 103982
Open AccessHaploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in the public Chilean national health system: A single center study
- 22 June 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (4) , e70111
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)
The characteristics at diagnosis and clinical course of primary extranodal follicular lymphoma (EFL) have not been extensively described. The International Extranodal Lymphoma Study Group (IELSG) conducted an international retrospective survey aimed to describe the clinical features at diagnosis and the outcomes of FL cases with a clinically dominant extranodal component. The dataset included 605 pathologically reviewed cases from 19 different countries, and their outcomes were compared to those of nodal follicular lymphomas. The two most common presentation sites for EFL were the skin (n = 334) and the gastrointestinal tract (n = 72), with 22 cases having primary duodenal localization. These subsets exhibited unique features at diagnosis and significantly different overall survival (OS) patterns. After a median follow‐up of 5.5 years, primary cutaneous lymphomas showed a superior outcome [10‐year OS: 89% (95% CI, 83%–93%)], while primary gastrointestinal lymphomas had an intermediate outcome [10‐year OS: 79% (95% CI, 59%–90%)]. Among the gastrointestinal lymphomas, primary duodenal lymphomas tended toward the best outcome [10‐year OS: 95% (95% CI, 69%–99%)]. Other primary extranodal sites had inferior outcomes [10‐year OS: 59% (95% CI, 48%–68%)], similar to primary nodal lymphomas [10‐year OS: 57% (95% CI, 49%–64%)]. These findings support the identification of specific primary FL localizations as distinct entities with particular clinical and biological characteristics.
- 22 June 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (4) , e70111
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)
The characteristics at diagnosis and clinical course of primary extranodal follicular lymphoma (EFL) have not been extensively described. The International Extranodal Lymphoma Study Group (IELSG) conducted an international retrospective survey aimed to describe the clinical features at diagnosis and the outcomes of FL cases with a clinically dominant extranodal component. The dataset included 605 pathologically reviewed cases from 19 different countries, and their outcomes were compared to those of nodal follicular lymphomas. The two most common presentation sites for EFL were the skin (n = 334) and the gastrointestinal tract (n = 72), with 22 cases having primary duodenal localization. These subsets exhibited unique features at diagnosis and significantly different overall survival (OS) patterns. After a median follow‐up of 5.5 years, primary cutaneous lymphomas showed a superior outcome [10‐year OS: 89% (95% CI, 83%–93%)], while primary gastrointestinal lymphomas had an intermediate outcome [10‐year OS: 79% (95% CI, 59%–90%)]. Among the gastrointestinal lymphomas, primary duodenal lymphomas tended toward the best outcome [10‐year OS: 95% (95% CI, 69%–99%)]. Other primary extranodal sites had inferior outcomes [10‐year OS: 59% (95% CI, 48%–68%)], similar to primary nodal lymphomas [10‐year OS: 57% (95% CI, 49%–64%)]. These findings support the identification of specific primary FL localizations as distinct entities with particular clinical and biological characteristics.
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400344
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study
PURPOSE: Hodgkin lymphoma (HL) is classified as the first malignancy to be cured by a combination of chemotherapy and radiotherapy. However, the life expectancy of HL survivors is hampered by the occurrence of late adverse events, including second malignant neoplasms (SMNs) and cardiovascular diseases (CVDs). PATIENTS AND METHODS: We investigated the causes of death in a cohort of 1,435 patients over age 15 years treated at 18 different public cancer centers in Chile. RESULTS: After a median follow-up of 19 years (0-37), the 5-year overall survival improved from 64% in the cohort 1985-1994 to 81% in the cohort 2009-2014 ( P < .001). HL was the main cause of death in the first 10 years after treatment, whereas SMN and CVD risk peaked 10-15 years and remained raised for 30 years or longer. Cumulative incidence of deaths (CIDs) due to SMNs resulted significantly higher in patients treated with cyclophosphamide, vincristine, procarbazine, prednisone (MOPP)/MOPP-like regimens over doxorubicin, bleomycin, vinblastine, dacarbazine. CIDs due to CVDs increased from 0.4 to 4.1 at 5 and 20 years, respectively. CONCLUSION: HL survivors continue to have a reduced life expectancy due to an increased risk of dying of SMNs and/or CVDs, although it was lower among patients treated in the most recent calendar period studied (2002-2014).
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400344
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study
PURPOSE: Hodgkin lymphoma (HL) is classified as the first malignancy to be cured by a combination of chemotherapy and radiotherapy. However, the life expectancy of HL survivors is hampered by the occurrence of late adverse events, including second malignant neoplasms (SMNs) and cardiovascular diseases (CVDs). PATIENTS AND METHODS: We investigated the causes of death in a cohort of 1,435 patients over age 15 years treated at 18 different public cancer centers in Chile. RESULTS: After a median follow-up of 19 years (0-37), the 5-year overall survival improved from 64% in the cohort 1985-1994 to 81% in the cohort 2009-2014 ( P < .001). HL was the main cause of death in the first 10 years after treatment, whereas SMN and CVD risk peaked 10-15 years and remained raised for 30 years or longer. Cumulative incidence of deaths (CIDs) due to SMNs resulted significantly higher in patients treated with cyclophosphamide, vincristine, procarbazine, prednisone (MOPP)/MOPP-like regimens over doxorubicin, bleomycin, vinblastine, dacarbazine. CIDs due to CVDs increased from 0.4 to 4.1 at 5 and 20 years, respectively. CONCLUSION: HL survivors continue to have a reduced life expectancy due to an increased risk of dying of SMNs and/or CVDs, although it was lower among patients treated in the most recent calendar period studied (2002-2014).
- Open Access
- 31 January 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (3) , 583-602
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer–cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In peripheral T-cell lymphoma–not otherwise specified and anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL), patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60 years, primary refractory disease, histological subtype other than angioimmunoblastic T-cell lymphoma (AITL), extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count less than the lower limit of normal. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL, in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14%, 23.3%, and 7%, respectively. Patients received either a "novel" single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK– ALCL. Among the SA, small-molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results highlight continued efficacy of novel drugs globally and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL.
- 31 January 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (3) , 583-602
Open AccessGlobal outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer–cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In peripheral T-cell lymphoma–not otherwise specified and anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL), patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60 years, primary refractory disease, histological subtype other than angioimmunoblastic T-cell lymphoma (AITL), extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count less than the lower limit of normal. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL, in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14%, 23.3%, and 7%, respectively. Patients received either a "novel" single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK– ALCL. Among the SA, small-molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results highlight continued efficacy of novel drugs globally and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL.
- Open Access
- 26 September 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (6) , e3312
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)
Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site (n = 24). The most common histological subtype was diffuse large B‐cell lymphoma (DLBCL, n = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first‐line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow‐up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5‐year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause‐specific, and progression‐free survival in patients with DLBCL.
- 26 September 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (6) , e3312
Open AccessSuperior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)
Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site (n = 24). The most common histological subtype was diffuse large B‐cell lymphoma (DLBCL, n = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first‐line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow‐up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5‐year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause‐specific, and progression‐free survival in patients with DLBCL.
- Open Access
- 22 September 2024
- Published by Wiley in Cancer Reports
- Vol. 7 (9) , e2126
Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy
Background: Follicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma (NHL) in the United States and Europe. However, data on FL from Latin America are scant.Aims: This study aims at better understand the clinical features, treatment patterns and outcomes of patients with FL in Chile. Of special interest was to evaluate POD24 as an adverse marker.Methods and Results: We collected retrospective data from 722 patients 15 years or older diagnosed with FL and treated in 17 cancer centers in Chile between 2000 and 2019. Time to first treatment (TTFT), progression‐free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Cox proportional‐hazard regression models were fitted to investigate prognostic factor. The median age at diagnosis was 62 with a female predominance (63%); 73% of patients had advance stage disease and 68% had bone marrow involvement; 63% had intermediate or high FLIPI scores. The 1‐year TTFT rate was 96%, and 30% of patients received chemoimmunotherapy. Adding rituximab to chemotherapy was associated with a higher complete response (69% vs. 60%; p < 0.001) and superior median OS (16 vs. 8 years; p < 0.001). Patients who experience POD24 had an inferior median OS (2.4 vs. 15 years).Conclusion: Our study shows a female predominance in patients with FL in Chile and confirms superior response and survival outcomes with adding rituximab to chemotherapy. Our study also confirms a poor OS in patients who experience POD24.
- 22 September 2024
- Published by Wiley in Cancer Reports
- Vol. 7 (9) , e2126
Open AccessFollicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy
Background: Follicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma (NHL) in the United States and Europe. However, data on FL from Latin America are scant.Aims: This study aims at better understand the clinical features, treatment patterns and outcomes of patients with FL in Chile. Of special interest was to evaluate POD24 as an adverse marker.Methods and Results: We collected retrospective data from 722 patients 15 years or older diagnosed with FL and treated in 17 cancer centers in Chile between 2000 and 2019. Time to first treatment (TTFT), progression‐free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Cox proportional‐hazard regression models were fitted to investigate prognostic factor. The median age at diagnosis was 62 with a female predominance (63%); 73% of patients had advance stage disease and 68% had bone marrow involvement; 63% had intermediate or high FLIPI scores. The 1‐year TTFT rate was 96%, and 30% of patients received chemoimmunotherapy. Adding rituximab to chemotherapy was associated with a higher complete response (69% vs. 60%; p < 0.001) and superior median OS (16 vs. 8 years; p < 0.001). Patients who experience POD24 had an inferior median OS (2.4 vs. 15 years).Conclusion: Our study shows a female predominance in patients with FL in Chile and confirms superior response and survival outcomes with adding rituximab to chemotherapy. Our study also confirms a poor OS in patients who experience POD24.
- Open Access
- 30 January 2024
- Published by Wiley
Incidence and clinical significance of FLT3 and nucleophosmin mutation in childhood acute myeloid leukemia in Chile.
Introduction. Acute myeloid leukemia (AML) is a heterogeneous disease and about one third do not have evident genetic abnormalities. The mutation of specific molecular markers such as fms-like tyrosine kinase 3 (FTL3) internal tandem duplication (ITD) and nucleophosmin (NPM1) are associated with an adverse and favorable prognosis, respectively. Objective. To determine the prevalence of FLT3/ITD and NPM1 in Chilean children under 18 years and its association with clinical data and prognosis. Results. Two hundred and thirty-two children with AML were studied between 2011-2017, median 8.6 years (range 1 month-18). Acute promyelocytic leukemia (APL) was diagnosed in 29%. FLT3/ITD mutated in non-promyelocytic AML was 10% (14/133), and FLT3/TKD 3.7% (2/54). In APL was 25.4% (16/63). In non-promyelocytic AML, FLT3/ITD mutated was associated with high leucocyte count, median 28.5 xmm3 (n=14) versus 19.4 xmm3 (n=119), (p=0.25) in unmutated cases. In APL was, median 33.6 xmm3 (n=15) versus 2.8 xmm3 (n=47), (p<0.001). Five-year overall survival (OS) in non-promyelocytic AML with unmutated and mutated FLT3/ITD, 62.7% and 21.4%, (p<0.001); 5-year event free survival (EFS) 79.5% and 50%, (p <0.01). Five-year OS in APL with unmutated and mutated FLT3/ITD was 84.7% and 62.5%, (p =0.05); while 5-year EFS was 84.7% and 68.8% (p =0.122). NPM1 mutation was observed in 3.2% (5/155), all non-promyelocytic AML with normal karyotype. Conclusion. FLT3/ITD mutation was observed more frequently in APL and associated with higher white cell count at diagnosis. However, the most important finding was that FLT3/ITD mutation was associated with lower survival in non-promyelocytic AML.
- 30 January 2024
- Published by Wiley
Open AccessIncidence and clinical significance of FLT3 and nucleophosmin mutation in childhood acute myeloid leukemia in Chile.
Introduction. Acute myeloid leukemia (AML) is a heterogeneous disease and about one third do not have evident genetic abnormalities. The mutation of specific molecular markers such as fms-like tyrosine kinase 3 (FTL3) internal tandem duplication (ITD) and nucleophosmin (NPM1) are associated with an adverse and favorable prognosis, respectively. Objective. To determine the prevalence of FLT3/ITD and NPM1 in Chilean children under 18 years and its association with clinical data and prognosis. Results. Two hundred and thirty-two children with AML were studied between 2011-2017, median 8.6 years (range 1 month-18). Acute promyelocytic leukemia (APL) was diagnosed in 29%. FLT3/ITD mutated in non-promyelocytic AML was 10% (14/133), and FLT3/TKD 3.7% (2/54). In APL was 25.4% (16/63). In non-promyelocytic AML, FLT3/ITD mutated was associated with high leucocyte count, median 28.5 xmm3 (n=14) versus 19.4 xmm3 (n=119), (p=0.25) in unmutated cases. In APL was, median 33.6 xmm3 (n=15) versus 2.8 xmm3 (n=47), (p<0.001). Five-year overall survival (OS) in non-promyelocytic AML with unmutated and mutated FLT3/ITD, 62.7% and 21.4%, (p<0.001); 5-year event free survival (EFS) 79.5% and 50%, (p <0.01). Five-year OS in APL with unmutated and mutated FLT3/ITD was 84.7% and 62.5%, (p =0.05); while 5-year EFS was 84.7% and 68.8% (p =0.122). NPM1 mutation was observed in 3.2% (5/155), all non-promyelocytic AML with normal karyotype. Conclusion. FLT3/ITD mutation was observed more frequently in APL and associated with higher white cell count at diagnosis. However, the most important finding was that FLT3/ITD mutation was associated with lower survival in non-promyelocytic AML.
- Open Access
- 28 August 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (17) , 5047-5054
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network
The natural history of limited-stage peripheral T-cell lymphomas (PTCLs) remains poorly defined. We investigated outcomes and prognostic variables in patients registered in the T-Cell Project (TCP) (#NCT01142674) to develop a model to predict overall survival (OS) for the common nodal PTCL subtypes (PTCL-NOS, AITL, ALCL). The model was validated in an independent data set from Australian and Brazilian registries. 211 patients registered in the TCP between 2006-2018 were studied. The median age was 59 years (range 18-88) and median follow-up was 49 months. One hundred twenty-seven patients (78%) received anthracycline-based regimens, 5 patients (3%) radiotherapy alone (RT), 24 patients (15%) chemotherapy+RT. 5-year OS and PFS were 47% and 37%, respectively. Age >60 years, elevated LDH and low serum albumin were independent prognostic factors. The model identified 3 groups with low- (26%, score 0), intermediate- (41%, score 1), and high-risk (33%, score 2-3) with 5-year OS of 78% (95% confidence interval [95% CI], 29-127), 46% (95% CI, 24-68), and 25% (95% CI, 20-30), respectively (P < 0.001) and 5-year PFS of 66% (95% CI, 33-99), 37% (95% CI, 9-65), and 17% (95% CI, 9-25), respectively (P < 0.001). The model demonstrated greater discriminatory power than established prognostic indices and an analogous distribution and outcomes in the 3 groups in the validation cohort of 103 patients. The SALENTO Model (Limited Stage Peripheral T-Cell Lymphoma Prognostic Model) is an objective, simple and robust prognostic tool. The high-risk group has poor outcomes, comparable to advanced stage disease, and should be considered for innovative first-line approaches.
- 28 August 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (17) , 5047-5054
Open AccessThe SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network
The natural history of limited-stage peripheral T-cell lymphomas (PTCLs) remains poorly defined. We investigated outcomes and prognostic variables in patients registered in the T-Cell Project (TCP) (#NCT01142674) to develop a model to predict overall survival (OS) for the common nodal PTCL subtypes (PTCL-NOS, AITL, ALCL). The model was validated in an independent data set from Australian and Brazilian registries. 211 patients registered in the TCP between 2006-2018 were studied. The median age was 59 years (range 18-88) and median follow-up was 49 months. One hundred twenty-seven patients (78%) received anthracycline-based regimens, 5 patients (3%) radiotherapy alone (RT), 24 patients (15%) chemotherapy+RT. 5-year OS and PFS were 47% and 37%, respectively. Age >60 years, elevated LDH and low serum albumin were independent prognostic factors. The model identified 3 groups with low- (26%, score 0), intermediate- (41%, score 1), and high-risk (33%, score 2-3) with 5-year OS of 78% (95% confidence interval [95% CI], 29-127), 46% (95% CI, 24-68), and 25% (95% CI, 20-30), respectively (P < 0.001) and 5-year PFS of 66% (95% CI, 33-99), 37% (95% CI, 9-65), and 17% (95% CI, 9-25), respectively (P < 0.001). The model demonstrated greater discriminatory power than established prognostic indices and an analogous distribution and outcomes in the 3 groups in the validation cohort of 103 patients. The SALENTO Model (Limited Stage Peripheral T-Cell Lymphoma Prognostic Model) is an objective, simple and robust prognostic tool. The high-risk group has poor outcomes, comparable to advanced stage disease, and should be considered for innovative first-line approaches.